Real World Retina: Challenges in the Management of Retinal Diseases—Focus on RVO and nAMD
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Activity Description
Pinnacle clinical studies utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapies for the management of retinal diseases have demonstrated significant visual and anatomical improvements. However, translating these promising results into real-world practice does not always result in comparable outcomes to clinical studies due to undertreatment and the loss of patient adherence because of treatment burden. New and emerging therapies with extended durations of action along with the refinement of personalized treatment protocols are helping to address treatment burden, while baseline factors and imaging techniques that assist with monitoring of therapy response have the potential to optimize visual and anatomical outcomes. In this monograph, experts in the field evaluate the evidence for anti-VEGF treatment outcomes for neovascular age-related macular degeneration (nAMD) and retinal vein occlusion (RVO) in clinical practice, identify prognostic indicators for predicting anti-VEGF therapy outcomes, and assess the latest evidence regarding safety, efficacy, and durability of new therapies for the management of nAMD and RVO.
Target Audience
The intended audience for this activity is retina specialists, ophthalmologists, and other healthcare professionals involved in the management of patients with retinal disorders.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate the evidence for anti-VEGF treatment outcomes in retinal vein occlusion in clinical practice.
- Identify patient factors that can assist in predicting anti-VEGF therapy outcomes in patients with retinal vein occlusion.
- Assess the applicability of recent advances in imaging for monitoring treatment response in patients with retinal vein occlusion.
- Evaluate the evidence for anti-VEGF treatment outcomes in nAMD in clinical practice.
- Identify prognostic indicators for predicting anti-VEGF therapy outcomes in patients with nAMD.
- Assess the latest evidence about new treatments for nAMD, including their safety, efficacy, and durability.
Activity Co-Chairs
David Eichenbaum, MD
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
St. Petersburg, FL
Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH
Faculty
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV
Judy E. Kim, MD, FARVO, FASRS
Vice Chair of Education
Medical Director of Clinical Research
University of Texas Southwestern Medical Center
Dallas, TX
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Katherine E. Talcott, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic
Cleveland, OH
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Medical Writer
Valerie Zimmerman, PhD
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 30, 2023, to November 29, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
The articles in this monograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Eichenbaum, Khanani, Kim, Regillo, Singh, and Talcott during a live expert panel held on September 7 and 13, 2023. The content of this monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Activity Co-Chairs and Faculty report the following relevant financial relationship(s)
David Eichenbaum, MD
Consultant: Alimera, Allergan, Annexon, Apellis, Bausch + Lomb, Coherus, Crinetics, DORC, EyePoint, Genentech, Gyroscope, lVERIC bio, Kodiak, Novartis, Ocular Therapeutix, Opthea, Outlook, RecensMedical, Regeneron, Regenxbio, ReVive, Samsara, USRetina
Speaker Contracted by Ineligible Company: Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Genentech, IVERIC bio, Regeneron
Independent Research Contractor: 4DMT, Alexion, Alkahest, Allgenesis, Annexon, AsclepiX, Aviceda, Bayer, EyePoint, Gemini, Genentech/Roche, Gyroscope, Ionis, lVERIC bio, Janssen, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Opthea, ONL, RecensMedical, Regeneron, Regenxbio, Unity
Individual Stocks and Stock Options: Boston Image Reading Center, Janssen, Network Eye, ReVive, USRetina
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, Adverum, Alimera, Allergan, Apellis, AsclepiX, Aviceda, Bausch + Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, DORC, Gemini, Genentech, Glaukos, Graybug, Gyroscope, IVERIC bio, Janssen, Kato, Kodiak, Novartis, Oculis, Opthea, Oxurion, PolyPhotonix, RecensMedical, Regeneron, Retrotope, Regenxbio, RevOpsis, Roche, Thea, Unity Bio
Speaker Contracted by Ineligible Company: Allergan, Genentech, Novartis
Independent Research Contractor: 4DMT, Adverum, Apellis, AsclepiX, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, IVERIC bio, Kodiak, Neurotech, NGM, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxurion, RecensMedical, Regenxbio, Roche, Unity Bio
Individual Stocks and Stock Options: Aviceda, PolyPhotonix, RecensMedical, Retrotope
Judy E. Kim, MD, FARVO, FASRS
Consultant: Allergan, Apellis, Bausch + Lomb, Clearside, DORC, Genentech, Notal Vision, Novartis, Outlook Therapeutics, Regeneron
Independent Research Contractor: Heidelberg, Optos
Carl D. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Clearside, EyePoint, Genentech, Graybug, IVERIC bio, Janssen, Kodiak, Lineage Cell Therapeutics, Merck, NGM Bio, Novartis, Ocugen, Ocular Therapeutics, Opthea, Regenxbio, Stealth BioTherapeutics, Théa, Zeiss
Independent Research Contractor: Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Graybug, Gyroscope, IVERIC bio, Kodiak, Lineage Cell Therapeutics, NGM Bio, Notal Vision, Novartis, Ocugen, Opthea, Regeneron, Regenxbio
Individual Stocks and Stock Options: Aviceda, Ocugen
Rishi P. Singh, MD
Consultant: Alcon, Apellis, AsclepiX, Bausch + Lomb, Genentech, Gyroscope, IVERIC bio, Novartis, Regeneron
Katherine E. Talcott, MD
Consultant: Alimera, Apellis, Bausch + Lomb, EyePoint, Genentech
Speaker Contracted by Ineligible Company: Genentech, IVERIC bio, Zeiss
Independent Research Contractor: Regenxbio, Regeneron, Zeiss
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Medical Writer reports the following relevant financial relationship(s)
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com